Trial Profile

A multi-centre randomised double-blind placebo controlled clinical trial designed to evaluate EBX-102-02 for the treatment of Irritable Bowel Syndrome (IBS)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EBX 102 02 (Primary)
Indications Irritable bowel syndrome
Focus Adverse reactions
Acronyms TrIuMPH
Sponsors EnteroBiotix

Most Recent Events

06 May 2025 According to EnteroBiotix media release, data from this study was at Digestive Disease Week (DDW) 2025, taking place 3 to 6 May in San Diego, USA.
06 May 2025 Results presented in the EnteroBiotix media release.
28 Apr 2025 According to EnteroBiotix media release, data from this study will be presented at Digestive Disease Week(DDW) 2025, during 3 to 6 May in San Diego, USA.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com